These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 22666367)

  • 1. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
    Mir O; Coriat R; Blanchet B; Durand JP; Boudou-Rouquette P; Michels J; Ropert S; Vidal M; Pol S; Chaussade S; Goldwasser F
    PLoS One; 2012; 7(5):e37563. PubMed ID: 22666367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
    Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
    Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
    Lee SJ; Lee J; Park SH; Park JO; Park YS; Kang WK; Lee J; Yim DS; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1540-7. PubMed ID: 21695438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
    Yau T; Chan P; Ng KK; Chok SH; Cheung TT; Fan ST; Poon RT
    Cancer; 2009 Jan; 115(2):428-36. PubMed ID: 19107763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Chan SL; Lin CC; Chiorean EG; Holcombe RF; Mulcahy MF; Carter WD; Patel K; Wilson WR; Melink TJ; Gutheil JC; Tsao CJ
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):539-45. PubMed ID: 21594722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
    Gomo C; Coriat R; Faivre L; Mir O; Ropert S; Billemont B; Dauphin A; Tod M; Goldwasser F; Blanchet B
    Invest New Drugs; 2011 Dec; 29(6):1511-4. PubMed ID: 20706860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
    Boudou-Rouquette P; Ropert S; Mir O; Coriat R; Billemont B; Tod M; Cabanes L; Franck N; Blanchet B; Goldwasser F
    Oncologist; 2012; 17(9):1204-12. PubMed ID: 22752067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
    Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
    Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
    Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
    Vincenzi B; Santini D; Russo A; Addeo R; Giuliani F; Montella L; Rizzo S; Venditti O; Frezza AM; Caraglia M; Colucci G; Del Prete S; Tonini G
    Oncologist; 2010; 15(1):85-92. PubMed ID: 20051477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
    Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
    Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study.
    Lee S; Yoon SH; Park JY; Kim DY; Ahn SH; Han KH; Choi HJ
    Invest New Drugs; 2012 Jun; 30(3):1150-7. PubMed ID: 21249514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
    Di Costanzo GG; Tortora R; Iodice L; Lanza AG; Lampasi F; Tartaglione MT; Picciotto FP; Mattera S; De Luca M
    Dig Liver Dis; 2012 Sep; 44(9):788-92. PubMed ID: 22579445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study.
    Hidaka H; Nakazawa T; Kaneko T; Minamino T; Takada J; Tanaka Y; Okuwaki Y; Watanabe M; Shibuya A; Koizumi W
    J Gastroenterol; 2012 Sep; 47(9):1030-5. PubMed ID: 22402773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.